Successful closing of Araris Biotech Ltd CHF 2.5 million seed financing round
26. August 2019
Only six months after its incorporation, Araris Biotech Ltd has closed an oversubscribed seed financing round of CHF 2.5 million from Swiss venture capitalists Redalpine, Schroder Adveq and VI Partners.
Araris Biotech Ltd is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich pioneering a novel antibody-drug conjugate (ADC)-linker technology. Araris’ linker platform enables the attachment of any payload to “off the shelf” antibodies without the need of prior antibody engineering.
Araris Biotech Ltd was advised in all legal matters with regard to the seed financing round by Bader Gnehm & Partner. The team consisted of Oliver Gnehm (Partner) and Denis A. Parvex (Associate).